NLS Pharmaceutics AG
NLSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $898 | $1,016 | $655 |
| - Cash | $2 | $1 | $9 | $5 |
| + Debt | $0 | $2 | $0 | $0 |
| Enterprise Value | -$0 | $899 | $1,007 | $649 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$4 | -$12 | -$15 | -$12 |
| % Margin | – | – | – | – |
| Net Income | -$2 | -$12 | -$16 | -$12 |
| % Margin | – | – | – | – |
| EPS Diluted | -26.3 | -3.2 | -8.4 | -8.1 |
| % Growth | -721.9% | 61.9% | -3.7% | – |
| Operating Cash Flow | -$4 | -$10 | -$14 | -$15 |
| Capital Expenditures | -$0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$4 | -$10 | -$14 | -$15 |